AI-enhanced virtual reality martial arts training: how technology readiness, instructional design, usefulness, and instructor competency drive learning performance through cognitive absorption - Nature

When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: ShutterstockThe changing seasons can really affect your mood, especially as we move from those long days and warm evenings of summer into the cozy fall season. That's why your routine may need a switch-up, too. Maybe your body is craving a slower approach, or you just want to try something new. To help you, YogaRenew instructor Melie Purdon shares four yoga poses to help you feel grounded, energized and present as the weather cools. Wherever you choose to practice, these poses will help you feel calm, centered and ready to welcome the crisp fall air. This short routine is beginner-friendly and low-impact, which means you can build foundational strength while putting less stress and strain on your joints. One of the best yoga mats is also recommended, and that's all. Five yoga poses for grounding, strength and calmYoga improves mobility and flexibility and strengthens your body using your body weight and some props like blocks and straps. It helps shift your body into the parasympathetic nervous system, which can reduce stress and anxiety and boost relaxation.

Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity. IntroductionOvarian cancer is the second most common malignancy of the female genital tract in the United States, according to the American College of Obstetricians and Gynecologists, 2017.1 In terms of mortality, it ranked eighth worldwide in 2013 and fifth in Poland in 2019 among all cancers.2,3 The high mortality rate associated with ovarian cancer is mainly due to its late diagnosis. At the time of diagnosis, two-thirds of patients present with intraperitoneal dissemination, corresponding to International Federation of Gynecology and Obstetrics (FIGO) stage III or IV.4 The most important prognostic indicator in patients with advanced-stage ovarian cancer is the volume of residual disease after cytoreductive surgery.4 The primary treatment approach remains debulking surgery. The goal of this procedure is to achieve complete cytoreduction.

The investigational factor XI (FXI) monoclonal antibodies amrecibart and cenvacibart demonstrated successful anticoagulation with a favorable safety profile in preclinical and phase 1 clinical studies, representing a novel treatment strategy for patients with thrombosis. The results were published in Blood by Dan Chalothorn, PhD, of Regeneron Pharmaceuticals, and colleagues. The research team first compared the mechanisms and coagulation effects of amrecibart and cenvacibart with other FXI-targeted monoclonal antibodies in both human and nonhuman primate plasma using an in vitro functional clotting assay.1Targeting the Intrinsic PathwayWith unique FXI/FXIa-binding mechanisms, amrecibart and cenvacibart address an unmet need for novel treatments with a favorable risk-benefit profile because current standard-of-care anticoagulants carry a high risk for bleeding. Cenvacibart and amrecibart block FXI activity by targeting the catalytic domain and the apple 2 domain of FXI/FXIa, respectively. Although standard-of-care anticoagulants target the extrinsic coagulation pathway, these monoclonal antibodies specifically target the intrinsic coagulation pathway.